Henlius has obtained IND approval from NMPA for a Phase 1b/2 clinical study of its new PD-L1-targeting ADC, HLX43.

Nkarta announces approval for investigator-led study in Myasthenia Gravis and begins enrollment for Ntrust-2.

Denali Therapeutics has dosed the first participant in its Phase 2a trial for the LRRK2 inhibitor BIIB122, targeting Parkinson’s disease linked to LRRK2.

Duality Biologics and BioNTech shared encouraging interim findings for their experimental B7-H3 antibody-drug conjugate BNT324/DB-1311.

Simcha Therapeutics has announced the initiation of two clinical trials evaluating ST-067, their decoy-resistant IL-18, for hematological conditions.

Merck and Ridgeback Biotherapeutics have started a Phase 3 trial (MOVe-NOW) to assess LAGEVRIO™ (molnupiravir) in treating COVID-19 among high-risk adults.

IMFINZI® (durvalumab) has been authorized in the US as the first and sole immunotherapy treatment for patients with limited-stage small cell lung cancer.

Elritercept is an advanced investigational activin inhibitor aimed at treating anemia linked with specific hematologic malignancies.

Arrowhead Pharmaceuticals Seeks Approval to Start Phase 1/2a Trial of ARO-ALK7 for Obesity Treatment.

Jasper Therapeutics has reported the initial patient receiving treatment in the Phase 1b/2a ETESIAN trial of Briquilimab for asthma.

Epsilogen has declared the initiation of a Phase Ib trial assessing MOv18 IgE in individuals suffering from platinum-resistant ovarian cancer (PROC).

OncoC4 has received FDA approval for its IND application regarding AI-081, a promising PD-1/VEGF bispecific therapy for advanced solid tumors.